JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
Tel: +1-832-696-8203
Email: [email protected]
Worldwide Distributors
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
Verbascoside (Acteoside) is a hydroxytyrosol and phenylpropanoid sugar ester and an inhibitor of PKC and NF-κB [1].
Verbascoside has been found to decrease tyrosinase activity and melanin biosynthesis by regulating ERK signaling, and inhibit mycotoxin-mediated cell damage. In addition, Verbascoside has been reported to decrease the RANKL-stimulated differentiation of RAW264.7 cells and osteoclast formation. Moreover, Verbascoside has shown the inhibition of osteoclast formation in bone marrow macrophages （BMMs）with IC50 value of 4.8μM. Apart from these, Verbascoside has also been revealed to prevent these RANKL-induced increases in p-p38, p-ERK, p-JNK and the levels of phosphorylated MAPKs by immunometric analysis in macrophages. Furthermore, Verbascoside has been reported to inhibit RANKL-induced activation of NF-κB-DNA binding [1].
References:[1] Lee SY1, Lee KS, Yi SH, Kook SH, Lee JC. Acteoside suppresses RANKL-mediated osteoclastogenesis by inhibiting c-Fos induction and NF-κB pathway and attenuating ROS production. PLoS One. 2013 Dec 4;8(12):e80873. doi: 10.1371/journal.pone.0080873. eCollection 2013.
